[go: up one dir, main page]

SI3255061T1 - Selektivno imunsko osiromašenje niše endogenih matičnih celic za vsaditev - Google Patents

Selektivno imunsko osiromašenje niše endogenih matičnih celic za vsaditev

Info

Publication number
SI3255061T1
SI3255061T1 SI200732179T SI200732179T SI3255061T1 SI 3255061 T1 SI3255061 T1 SI 3255061T1 SI 200732179 T SI200732179 T SI 200732179T SI 200732179 T SI200732179 T SI 200732179T SI 3255061 T1 SI3255061 T1 SI 3255061T1
Authority
SI
Slovenia
Prior art keywords
immunodepletion
engraftment
selective
stem cell
cell niche
Prior art date
Application number
SI200732179T
Other languages
English (en)
Inventor
Irving L. Weissman
Agnieszka Czechowicz
Deepta Bhattacharya
Daniel Kraft
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39468595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3255061(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of SI3255061T1 publication Critical patent/SI3255061T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
SI200732179T 2006-11-03 2007-11-02 Selektivno imunsko osiromašenje niše endogenih matičnih celic za vsaditev SI3255061T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85643506P 2006-11-03 2006-11-03
EP17168021.8A EP3255061B1 (en) 2006-11-03 2007-11-02 Selective immunodepletion of endogenous stem cell niche for engraftment

Publications (1)

Publication Number Publication Date
SI3255061T1 true SI3255061T1 (sl) 2021-09-30

Family

ID=39468595

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200732179T SI3255061T1 (sl) 2006-11-03 2007-11-02 Selektivno imunsko osiromašenje niše endogenih matičnih celic za vsaditev

Country Status (9)

Country Link
US (5) US20100226927A1 (sl)
EP (3) EP3255061B1 (sl)
DK (1) DK2088864T3 (sl)
ES (2) ES2642205T3 (sl)
HU (1) HUE034583T2 (sl)
PL (1) PL3255061T3 (sl)
PT (1) PT3255061T (sl)
SI (1) SI3255061T1 (sl)
WO (1) WO2008067115A2 (sl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100226927A1 (en) 2006-11-03 2010-09-09 Weissman Irving L Selective immunodepletion of endogenous stem cell niche for engraftment
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
CA2829804A1 (en) * 2011-03-29 2012-10-04 Geron Corporation Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells
TWI596113B (zh) 2012-07-25 2017-08-21 塞爾德克斯醫療公司 抗ｋｉｔ抗體及其用途
EP2961828A4 (en) * 2013-02-28 2016-08-03 Harvard College COMPOSITIONS AND METHOD FOR MOBILIZING STEM CELLS
CN113975386A (zh) 2014-05-23 2022-01-28 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
DK3656869T4 (da) 2014-08-26 2025-05-19 Univ Leland Stanford Junior Transplantation af stamceller med en kombination af et stof, som er rettet mod stamceller, og modulation af immunregulatorisk signalering
US10889646B2 (en) 2015-03-25 2021-01-12 Children's Hospital Medical Center Use of KIT inhibitors to condition subjects for a hematopoietic stem cell (HSC) transplantation
HK1256681A1 (zh) * 2015-04-06 2019-10-04 President And Fellows Of Harvard College 用於非清髓性預處理的組合物和方法
EA039364B1 (ru) * 2015-10-09 2022-01-18 Президент Энд Феллоус Оф Гарвард Колледж Композиции и способы для немиелоаблативного кондиционирования
US9957576B2 (en) 2016-04-21 2018-05-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
EP3471772A4 (en) 2016-06-17 2020-03-18 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cells
BR112018076306A2 (pt) * 2016-06-17 2019-03-26 Magenta Therapeutics, Inc. composições e métodos para a supressão de células cd117+
US20200040093A1 (en) * 2016-10-13 2020-02-06 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
WO2018083071A1 (en) * 2016-11-02 2018-05-11 Universität Basel Immunologically discernible cell surface variants for use in cell therapy
JOP20190155A1 (ar) * 2016-12-21 2019-06-23 Novartis Ag مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
WO2018136606A1 (en) * 2017-01-18 2018-07-26 Thalia Papayannopoulou Compositions and methods for transplant recipient conditioning
MX395639B (es) 2017-01-20 2025-03-25 Heidelberg Pharma Res Gmbh Composiciones y métodos para el agotamiento de células cd137+.
BR112019015342A2 (pt) * 2017-01-30 2020-03-10 The Board Of Trustees Of The Leland Stanford Junior University Regime de condicionamento não genotóxico para o transplante de células-tronco
US11744861B2 (en) * 2017-03-13 2023-09-05 Poseida Therapeutics, Inc. Compositions and methods for selective elimination and replacement of hematopoietic stem cells
AU2018354189A1 (en) 2017-10-24 2020-04-23 Crispr Therapeutics Ag Compositions and methods for the depletion of CD117+ cells
CN111372608B (zh) 2017-10-24 2024-07-02 克里斯珀医疗股份公司 用于耗尽cd117+细胞的组合物和方法
AU2018374283A1 (en) 2017-11-29 2020-06-04 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD5+ cells
WO2019113437A1 (en) 2017-12-08 2019-06-13 The Board Of Trustees Of The Leland Stanford Junior University Hematopoietic stem cell engraftment
AU2019265019A1 (en) 2018-05-11 2020-11-26 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
TW202014209A (zh) 2018-06-20 2020-04-16 瑞士商諾華公司 用於消融造血幹細胞之抗體藥物軛合物
EA202190986A1 (ru) 2018-11-26 2021-12-14 Фоти Севен, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit
CN113166727A (zh) * 2018-11-28 2021-07-23 四十七公司 对消融方案耐受的基因修饰的hspc
WO2020219775A1 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anti-cd117 antibody-drug conjugates and uses thereof
CN118076642A (zh) * 2021-10-04 2024-05-24 美国政府卫生与公众服务部 抗cmpl二价scfv及其用途
WO2023183555A1 (en) * 2022-03-25 2023-09-28 Memorial Sloan-Kettering Cancer Center Method of promoting thymic recovery by administering hematopoietic stem cells with low c-kit expression
EP4516807A1 (en) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions for use in a method of providing improved hematopoietic stem cell engraftment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3213314B2 (ja) 1991-04-05 2001-10-02 ボード・オブ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・ワシントン 幹細胞因子レセプターに対するモノクローナル抗体
GB9323199D0 (en) 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
CN1291231B (zh) 1996-10-01 2010-06-02 杰龙公司 人类的端粒酶催化亚单位
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
WO2001046384A2 (en) 1999-12-23 2001-06-28 Cornell Research Foundation, Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
WO2001066139A1 (en) * 2000-03-06 2001-09-13 University Of Kentucky Research Foundation Use of a compound that selectively binds to cd123 to impair hematologic cancer progenitor cell
WO2003028711A2 (en) 2001-09-27 2003-04-10 Novartis Ag Use of c-kit inhibitors for the treatment of myeloma
US20030099621A1 (en) * 2001-11-29 2003-05-29 Robert Chow Stem cell screening and transplantation therapy for HIV infection
AU2003245752A1 (en) * 2002-06-28 2004-01-19 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
US20100226927A1 (en) 2006-11-03 2010-09-09 Weissman Irving L Selective immunodepletion of endogenous stem cell niche for engraftment

Also Published As

Publication number Publication date
EP3960764A1 (en) 2022-03-02
DK2088864T3 (en) 2017-10-02
ES2882360T3 (es) 2021-12-01
PT3255061T (pt) 2021-07-26
EP3255061B1 (en) 2021-06-16
US11905333B2 (en) 2024-02-20
WO2008067115A3 (en) 2008-11-06
HUE034583T2 (en) 2018-02-28
US20230128340A1 (en) 2023-04-27
EP2088864B1 (en) 2017-08-16
US20100226927A1 (en) 2010-09-09
ES2642205T3 (es) 2017-11-15
US10072091B2 (en) 2018-09-11
WO2008067115A2 (en) 2008-06-05
US20180327507A1 (en) 2018-11-15
PL3255061T3 (pl) 2021-12-06
EP2088864A4 (en) 2010-09-29
EP3255061A1 (en) 2017-12-13
EP2088864A2 (en) 2009-08-19
US20240400709A1 (en) 2024-12-05
US20170066834A1 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
PT3255061T (pt) Imunodepleção seletiva de nicho de células estaminais endógenas para enxerto
ZA200809978B (en) Method for selection of transformed cells
IL205951A0 (en) Method of inhibition of leukemic stem cells
GB2440690B (en) Sealing structure of refrigerator
GB2458863B (en) Improved culture of stem cells
SG138570A1 (en) Growth of embryonic stem cells
ZA200900956B (en) Tumor suppression using placental stem cells
EP2005083A4 (en) EATING DEVICE FOR REFRIGERATOR
PL2073842T5 (pl) Zastosowanie ludzkich komórek pochodzących z białaczki szpikowej do ekspresji przeciwciał
HUE054629T2 (hu) Akkumulátor teljesítménykorlátainak prediktív meghatározása
IL195826A0 (en) Placental niche and use thereof to culture stem cells
EP2142863A4 (en) CONTROL METHOD FOR REFRIGERATOR
EP2069477A4 (en) CHEMOREPULSION OF CELLS
EP2142869A4 (en) METHOD FOR CONTROLLING A REFRIGERATOR
GB0705854D0 (en) Methods of construction
IL206185A0 (en) Method for expanding hematopoietic stem cells using heterocyclic compound
ZA200901912B (en) Use of human cells of myeloid leukaemia origin for expression of antibodies
EP2305223A4 (en) AGENT FOR THE ACTIVATION OF STEM CELLS
EP1954801A4 (en) METHOD FOR ISOLATING CELLS
TWM299804U (en) Structure of leak-proof valve
TWM300647U (en) Improved structure for automatic pipe sealer of low-temperature storage pipe
TWM300223U (en) Improved structure of drain
AU2007906462A0 (en) Method of Storing Stem Cells
TWM299839U (en) Improved ice storage
GB0510465D0 (en) Water for deserts - the solar fridge